Ear infections are a widespread affair among the kids, causing fever, pain, and in worst case hearing loss, and still, most of the cases are misdiagnosed due to the doctors’ carelessness.
FREMONT, CA: The number of cases that are misdiagnosed is rising due to doctors’ inability to go deep into the middle ear where the infection resides. Currently, the U.S. FDA has given a green signal to Tomi Scope, which is a first-in-class technology, that enables the doctors to not only detect the presence or absence of fluid in the middle ear but also characterizes the type of fluid found. Tomi Scope is for noninvasive imaging of the middle ear, it had never been done in the past, and it is a huge step forward in assessing middle ear infections.
Physicians have been relying on the otoscope to screen for illness during regular exams and investigate earaches and any other ear symptoms for nearly two centuries. These devices can view the ear canal and eardrum but lack the capability to view the middle ear, which is vital in detecting middle ear infections. Out of more than 80 percent children who are affected by this infection, 50 percent are misdiagnosed using an otoscope, which leads in recurrent infections, the use of increasingly potent antibiotics and surgery is also increased. Every year more than 1 million children in the U.S. have ear tubes placed in their ears to help in draining the fluid from the middle ear.
Tomi Scope uses optical coherence technology (OCT) a high-resolution depth imaging which a noninvasive technique that depends on near-infrared light waves to evoke 3D views within living tissue, similar to ultrasound using sound waves.
The approach consists of a hand-held piece, tethered into a portable or a wall-mountable console for analyzing and sharing pictures with the patients and their parents on time. It presents a real-time view of the surface image and that a traditional otoscope captures but with the high quality and more in-depth imaging of what lies behind the eardrum, both.
Series A Round Underway
Tomi Scope is set to be released immediately through an early access program with a nationwide launch. At present, the primary focus is on paediatricians and urgent care clinics, still, Tomi Scope promises a broad range of potential customers who regularly diagnose ear infections like, family and general practitioners, and ENT’s, to be able to leverage it.